PUBLICATIONS, NEWS & EVENTS
Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis
Paper in the European Journal of Medicinal Chemistry discloses…
November 19, 2024/by adminEnterprise Therapeutics granted ‘rare pediatric disease designation’ in the US for novel cystic fibrosis investigational therapy ETD001
ETD001 is a novel, first in class blocker of the epithelial…
September 26, 2024/by adminEnterprise Therapeutics appoints Annabella Amatulli as Head of Regulatory Affairs
Appointment brings extensive regulatory experience as lead…
September 11, 2024/by adminEnterprise Therapeutics Doses First Person with Cystic Fibrosis in Phase 2 Trial for Novel Therapy ETD001
Trial aims to deliver clinical proof-of-concept and assess…
July 23, 2024/by adminEnterprise Therapeutics appoints Dr Renu Gupta as Chief Medical Officer and Dr Janet Hammond as Non-Executive Director
Appointments bring additional respiratory and late clinical-stage…
June 17, 2024/by adminEnterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker
Low doses of ETD001 demonstrate exceptionally long duration…
June 12, 2024/by adminEnterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing
Round led by new investor Panakes, with participation from…
January 30, 2024/by adminEnterprise Therapeutics appoints Dr Niyati Prasad as Chief Medical Officer
Dr Prasad will lead Enterprise’s development strategy to support…
February 8, 2022/by adminEnterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001
ETD001 is a novel inhaled, long-acting ENaC inhibitor
Therapy…
June 14, 2021/by adminTherapy…
Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche
Enterprise’s novel TMEM16A potentiator portfolio includes…
October 7, 2020/by adminEnterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002
ETD002 is a novel TMEM16A chloride channel potentiator
…
August 17, 2020/by admin…
Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer
Dr Morris will lead Enterprise’s therapeutics development strategy…
February 10, 2020/by admin
